Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant

Pécout, Marie; Cosson, Michel; Collinet, Pierre; Rubod, Chrystèle; Giraudet, Géraldine

doi:10.1016/j.jogoh.2019.03.015

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Гистероскопическую миомэктомию выполняют для удаления небольших подслизистых миом 0 или 1 типа [6], не превышающих 4-5 см в диаметре 3 . Некоторые миомы невозможно удалить за одну операцию.…”

Section: лапаротомияunclassified

“…Медикаментозное или хирургическое лечение бессимптомной миомы не предусмотрено клиническими рекомендациями. Необходимо учитывать, что в большинстве случаев размер миоматозных узлов при динамическом наблюдении прогрессивно увеличивается [3,4], что может осложнить реализацию репродуктивных планов. Предиктивная медикаментозная терапия бессимптомных миом у пациенток с репродуктивными планами пока не нашла подтверждения с позиций доказательной медицины, что требует проведения дальнейших исследований.…”

Section: Introductionunclassified

See 1 more Smart Citation

Modern approaches to the management of pregnancy in uterine myoma

Фаткуллин

Orlov

Фаткуллин

2023

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

The presented review summarizes current data on the tactics of accompanying patients with uterine myoma at various stages of their reproductive potential realization: the stage of pregravid preparation, the stage of pregnancy management, the moment of delivery and the postpartum period. Based on the analysis of domestic and foreign special scientific and practical literature, various methods of childbirth are proposed, from more preferable delivery through the natural birth canal, to the necessary caesarean section, performed strictly according to indications. Data are presented on the options for elective and emergency myomectomy during pregnancy, during operative delivery and in the postpartum period. Based on the results of systematization of the information received, the authors raise the question of the need for further research in the field of developing methods for optimal management of patients during pregnancy and childbirth complicated by uterine myoma, due to the relevance of the problems discussed.

show abstract

Section: лапаротомияunclassified

Section: Introductionunclassified

Modern approaches to the management of pregnancy in uterine myoma

Фаткуллин

Orlov

Фаткуллин

2023

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

show abstract

Contemporary approaches in the management of uterine leiomyomas

Singh

Kumar

Kavita

et al. 2023

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility

et al. 2020

View full text Add to dashboard Cite

Selective progesterone receptor modulators (SPRMs) are a new class of compounds developed to target the progesterone receptor (PR) with a mix of agonist and antagonist properties. These compounds have been introduced for the treatment of several gynecological conditions based on the critical role of progesterone in reproduction and reproductive tissues. In patients with uterine fibroids, mifepristone and ulipristal acetate have consistently demonstrated efficacy, and vilaprisan is currently under investigation, while studies of asoprisnil and telapristone were halted for safety concerns. Mifepristone demonstrated utility for the management of endometriosis, while data are limited regarding the efficacy of asoprisnil, ulipristal acetate, telapristone, and vilaprisan for this condition. Currently, none of the SPRMs have shown therapeutic success in treating endometrial cancer. Multiple SPRMs have been assessed for efficacy in treating PR-positive recurrent breast cancer, with in vivo studies suggesting a benefit of mifepristone, and multiple in vitro models suggesting the efficacy of ulipristal acetate and telapristone. Mifepristone, ulipristal acetate, vilaprisan, and asoprisnil effectively treated heavy menstrual bleeding (HBM) in patients with uterine fibroids, but limited data exist regarding the efficacy of SPRMs for HMB outside this context. A notable class effect of SPRMs are benign, PR modulator-associated endometrial changes (PAECs) due to the actions of the compounds on the endometrium. Both mifepristone and ulipristal acetate are effective for emergency contraception, and mifepristone was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of Cushing’s syndrome due to its additional antiglucocorticoid effect. Based on current evidence, SPRMs show considerable promise for treatment of several gynecologic conditions.

show abstract

Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant

Cited by 4 publications

References 12 publications

Modern approaches to the management of pregnancy in uterine myoma

Modern approaches to the management of pregnancy in uterine myoma

Contemporary approaches in the management of uterine leiomyomas

Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility

Contact Info

Product

Resources

About